Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
clinical pharmacology
hematology
pediatrics
pharmacokinetics and drug metabolism
transplantation
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
04
2020
accepted:
15
09
2020
pubmed:
9
10
2020
medline:
21
12
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
Total pancreatectomy with islet autotransplantation is a complex surgical approach for acute recurrent or chronic pancreatitis that frequently triggers extreme thrombocytosis (platelets ≥ 1000 × 10
Substances chimiques
Hydroxyurea
X6Q56QN5QC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-554Informations de copyright
© 2020, The American College of Clinical Pharmacology.
Références
Wilson GC, Sutton JM, Abbott DE, et al. Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? Ann Surg. 2014;260(4):659-665; discussion 665-657.
Chinnakotla S, Radosevich DM, Dunn TB, et al. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. J Am Coll Surg. 2014;218(4):530-543.
Bondoc AJ, Abu-El-Haija M, Nathan JD. Pediatric pancreas transplantation, including total pancreatectomy with islet autotransplantation. Semin Pediatr Surg. 2017;26(4):250-256.
Chinnakotla S, Beilman GJ, Dunn TB, et al. Factors predicting outcomes after a total pancreatectomy and islet autotransplantation lessons learned from over 500 cases. Ann Surg. 2015;262(4):610-622.
Chinnakotla S, Bellin MD, Schwarzenberg SJ, et al. Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indication, surgical techniques, postoperative management, and long-term outcomes. Ann Surg. 2014;260(1):56-64.
Naziruddin B, Iwahashi S, Kanak MA, Takita M, Itoh T, Levy MF. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant. 2014;14(2):428-437.
Boucher AA, Luchtman-Jones L, Palumbo JS, et al. Extreme thrombocytosis after pediatric pancreatectomy with islet autotransplantation is unique compared to other postsplenectomy states. J Pediatr Surg. 2020;55(8):1645-1650.
Robbins AJ, Skube ME, Bellin MD, et al. Portal vein thrombosis after total pancreatectomy and islet autotransplant: prophylaxis and graft impact. Pancreas. 2019;48(10):1329-1333.
Nandy P, Lien EJ, Avramis VI. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis. Anticancer Res. 1999;19(3A):1625-1633.
Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
Löfvenberg E, Nilsson T, Wahlin A, Jacobsson L. Hydroxyurea treatment of myeloproliferative disorders. Macro-megaloblastic blood and bone marrow changes. Acta Med Scand. 1987;222(2):169-174.
Ware RE, McGann PT, Quinn CT. Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatr Blood Cancer. 2019;66(8):e27778.
Estepp JH, Wiczling P, Moen J, et al. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure. Br J Clin Pharmacol. 2018;84(7):1478-1485.
Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998;91(5):1533-1541.
Newman EM, Carroll M, Akman SA, et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1997;39(3):254-258.
Paule I, Sassi H, Habibi A, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis. 2011 May 28;6:30.
Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 1998;34(5):347-358.
McGann PT, Niss O, Dong M, et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol. 2019;94(8):871-879.
Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
Kotagal M, Slusher J, Ahmad S, et al. In-hospital and 90-day outcomes after total pancreatectomy with islet autotransplantation for pediatric chronic and acute recurrent pancreatitis. Am J Transplant. 2019;19(4):1187-1194.
TPIAT for Pancreas Disorders. Cincinnati Children's Hospital Medical Center. https://care.cincinnatichildrens.org/pancreas/tpiat. Published 2019. Accessed June 1, 2020.
Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413-420.
Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation. 2004;77(5):741-747.
Habtemariam B. Hydroxyurea Review, Office of Clinical Pharmacology. United States Federal Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208843Orig1s000ClinPharmR.pdf. Published 2017. Accessed June 7, 2020.
Estepp JH, Melloni C, Thornburg CD, et al. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol. 2016;56(3):298-306.
Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol. 2016;81(4):742-752.
Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003-1009.
Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis. 2017;24(6):348-356.
Marahatta A, Ware RE. Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells Mol Dis. 2017;67:135-142.
Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155-163.
Dong M, Mizuno T, Vinks AA. Opportunities for model-based precision dosing in the treatment of sickle cell anemia. Blood Cells Mol Dis. 2017;67:143-147.
Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000;105(2):125-133.
Gurria JP, Boucher AA, Hornung L, et al. Thrombopoietin contributes to extreme thrombocytosis after pediatric pancreatectomy with islet autotransplantation. Pancreas. 2019;48(5):652-655.
Ichikawa N, Kitano K, Shimodaira S, et al. Changes in serum thrombopoietin levels after splenectomy. Acta Haematol. 1998;100(3):137-141.
Badawy SM. The use of hydroxyurea and leukapheresis in childhood acute leukemia with hyperleukocytosis. J Pediatr Hematol Oncol. 2016;38(5):407.
Reiss UM, Bensimhon P, Zimmerman SA, Ware RE. Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease. Am J Hematol. 2007;82(8):740-743.
Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281-291.
Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm. 2011;68(23):2241-2247.
Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262-269.
Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy 2010;30(2):217.
Lebensburger JD, Aban I, Pernell B, et al. Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy. Am J Hematol. 2019;94(4):417-423.